Riskpilot← Back to searchSign inGet full accessAttaDERM AB
ABActiveOrg 5591487128Skyttelinjen 48Medical specialists activities · NACE 8622Est. 20180 employees
Revenue 2025
SEK 511K
-32% vs 2024
EBITDA margin
56.5%
+184% vs 2024
Equity ratio
56.0%
Financial strength
Net profit 2025
SEK 229K
+121% vs 2024
| Revenue | SEK 511K | -32% |
| EBITDA | SEK 289K | +184% |
| Net profit | SEK 229K | +121% |
| Total assets | SEK 1,3M | +80% |
| Equity | SEK 753K | +44% |
| Employees | 0 | — |
Legal name
AttaDERM AB
Org number
5591487128
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
9 februari 2018
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Aktiebolaget ska bedriva hudläkarverksamhet och forskning och utveckling inom hälso- och sjukvårdsområdet, samt äga och förvalta värdepapper samt annan därmed förenlig verksamhet
Address
Skyttelinjen 48
Email
anahita.attaran@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 282 | 1 247 | 119 | 755 | 511 |
| Staff expenses | — | −847 | −812 | −634 | −428 |
| EBITDA | 559 | 354 | −704 | 102 | 289 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 559 | 354 | −704 | 102 | 289 |
| Net financials | −1 | 1 | 9 | 2 | −0 |
| Profit before tax | 418 | 265 | −278 | 104 | 289 |
| Tax | −87 | −55 | — | — | −60 |
| Net profit | 331 | 210 | −278 | 104 | 229 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 624 | 1 756 | 950 | 746 | 1 346 |
| Equity | 860 | 886 | 421 | 524 | 753 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 436 | 452 | 529 | 221 | 592 |
| Total debt | 436 | 452 | 529 | 221 | 592 |
EBITDA margin
56.5%
This company
15.8%
Market median
+258% vs market
20212025
Equity ratio
56.0%
This company
38.2%
Market median
+47% vs market
20212025
Return on equity
30.4%
This company
18.4%
Market median
+65% vs market
20212025
Net profit margin
44.8%
This company
8.1%
Market median
+453% vs market
20212025
Asset turnover
0.38×
This company
1.12×
Market median
-66% vs market
20212025
Debt / equity
0.79×
This company
0.62×
Market median
+27% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of AttaDERM AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anahita Attaran | Board of Directors | 0 companies |
| Sina Attaran | Board of Directors | 0 companies |